600161 天坛生物
2025/12 -
人民幣(K¥)

变动
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入6,168,0362.26%5,180,4424,261,3054,112,1563,445,595
减:营业总成本4,315,50922.68%3,429,7642,906,7942,873,2252,366,126
    其中:营业成本3,463,23226.75%2,550,7212,170,0242,157,6871,743,664
               财务费用(2,061)-93.74%(49,525)(57,989)(64,148)(30,304)
               资产减值损失(19,111)-63.95%(2,167)(2,254)(15,146)(917)
公允价值变动收益------------
投资收益26,979-57.80%37,21328,12712,0001,153
    其中:对联营企业和合营企业的投资收益------------
营业利润1,837,308-28.17%1,804,9951,432,1151,244,9071,104,537
利润总额1,822,724-28.44%1,798,5981,426,2731,241,0181,104,872
减:所得税费用332,842-23.48%289,140221,598172,204161,796
净利润1,489,882-29.47%1,509,4591,204,6751,068,814943,077
减:非控股权益399,044-29.13%399,570323,758308,802304,070
股东净利润1,090,838-29.59%1,109,889880,916760,012639,007

市场价值指针
每股收益 (元) *0.550-29.49%0.5600.5300.4700.510
每股派息 (元) *0.200100.00%0.1500.0500.1000.100
每股净资产 (元) *5.9355.35%5.9615.3405.8643.602
审计意见 #标准无保留意见标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容